Vanguard Group Inc. Cuts Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Vanguard Group Inc. lessened its position in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 1.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,869,079 shares of the biotechnology company’s stock after selling 58,518 shares during the quarter. Vanguard Group Inc. owned about 0.07% of Aldeyra Therapeutics worth $12,652,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new position in shares of Aldeyra Therapeutics in the 4th quarter worth approximately $39,000. NorthRock Partners LLC purchased a new position in shares of Aldeyra Therapeutics in the 4th quarter worth approximately $42,000. Kingswood Wealth Advisors LLC purchased a new position in shares of Aldeyra Therapeutics in the 1st quarter worth approximately $49,000. BNP Paribas Financial Markets boosted its holdings in shares of Aldeyra Therapeutics by 23.4% in the 1st quarter. BNP Paribas Financial Markets now owns 25,278 shares of the biotechnology company’s stock worth $83,000 after purchasing an additional 4,797 shares during the period. Finally, Denali Advisors LLC purchased a new position in shares of Aldeyra Therapeutics in the 1st quarter worth approximately $155,000. Hedge funds and other institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics Stock Down 0.8 %

ALDX opened at $4.71 on Wednesday. The business has a fifty day moving average of $3.73 and a 200 day moving average of $3.69. Aldeyra Therapeutics, Inc has a 52-week low of $1.42 and a 52-week high of $7.88. The stock has a market cap of $279.84 million, a P/E ratio of -9.25 and a beta of 1.45.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Oppenheimer reiterated an “outperform” rating and issued a $10.00 target price on shares of Aldeyra Therapeutics in a report on Monday, May 6th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Aldeyra Therapeutics in a report on Friday, August 9th. Finally, StockNews.com cut Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 22nd.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-?B, inflammasomes, and Scavenger Receptor A.